TY - JOUR
T1 - Effects of High-Pressure Processing, UV-C Irradiation and Thermoultrasonication on Donor Human Milk Safety and Quality
AU - Kontopodi, Eva
AU - Stahl, Bernd
AU - van Goudoever, Johannes B
AU - Boeren, Sjef
AU - Timmermans, Rian A H
AU - den Besten, Heidy M W
AU - Van Elburg, Ruurd M
AU - Hettinga, Kasper
N1 - Funding Information:
We would like to thank the Dutch Human Milk Bank for providing DHM samples. Additionally, we gratefully acknowledge the support of Jiska Oostveen, Mirte Doomen, Roosje de Jong, Jaap Hulstein, Louise Nederhoff, and Mariette Helmond in the experimental execution.
Publisher Copyright:
Copyright © 2022 Kontopodi, Stahl, van Goudoever, Boeren, Timmermans, den Besten, Van Elburg and Hettinga.
PY - 2022/3/21
Y1 - 2022/3/21
N2 - Holder pasteurization (HoP) is the current recommended treatment for donor human milk. Although this method inactivates microbial contaminants, it also negatively affects various milk components. High-pressure processing (HPP, 400, 500, and 600 MPa), ultraviolet-C irradiation (UV-C, 2,430, 3,645, and 4,863 J/L) and thermoultrasonication (TUS, 1,080 and 1,620 kJ/L) were investigated as alternatives to thermal pasteurization (HoP). We assessed the effects of these methods on microbiological safety, and on concentration and functionality of immunoglobulin A, lactoferrin, lysozyme and bile salt-stimulated lipase, with LC-MS/MS-based proteomics and activity assays. HoP, HPP, TUS, and UV-C at 4863 J/L, achieved >5-log
10 microbial reduction. Native protein levels and functionality showed the highest reduction following HoP, while no significant reduction was found after less intense HPP and all UV-C treatments. Immunoglobulin A, lactoferrin, and lysozyme contents were also preserved after low intensity TUS, but bile salt-stimulated lipase activity was significantly reduced. This study demonstrated that HPP and UV-C may be considered as suitable alternatives to HoP, since they were able to ensure sufficient microbial inactivation while at the same time better preserving the bioactive components of donor human milk. In summary, our results provide valuable insights regarding the evaluation and selection of suitable processing methods for donor human milk treatment, which may replace HoP in the future.
AB - Holder pasteurization (HoP) is the current recommended treatment for donor human milk. Although this method inactivates microbial contaminants, it also negatively affects various milk components. High-pressure processing (HPP, 400, 500, and 600 MPa), ultraviolet-C irradiation (UV-C, 2,430, 3,645, and 4,863 J/L) and thermoultrasonication (TUS, 1,080 and 1,620 kJ/L) were investigated as alternatives to thermal pasteurization (HoP). We assessed the effects of these methods on microbiological safety, and on concentration and functionality of immunoglobulin A, lactoferrin, lysozyme and bile salt-stimulated lipase, with LC-MS/MS-based proteomics and activity assays. HoP, HPP, TUS, and UV-C at 4863 J/L, achieved >5-log
10 microbial reduction. Native protein levels and functionality showed the highest reduction following HoP, while no significant reduction was found after less intense HPP and all UV-C treatments. Immunoglobulin A, lactoferrin, and lysozyme contents were also preserved after low intensity TUS, but bile salt-stimulated lipase activity was significantly reduced. This study demonstrated that HPP and UV-C may be considered as suitable alternatives to HoP, since they were able to ensure sufficient microbial inactivation while at the same time better preserving the bioactive components of donor human milk. In summary, our results provide valuable insights regarding the evaluation and selection of suitable processing methods for donor human milk treatment, which may replace HoP in the future.
KW - antimicrobial proteins
KW - bacteria inactivation
KW - bacteriostatic properties
KW - donor human milk
KW - non-thermal processing
KW - proteomics
UR - http://www.scopus.com/inward/record.url?scp=85127967652&partnerID=8YFLogxK
U2 - 10.3389/fped.2022.828448
DO - 10.3389/fped.2022.828448
M3 - Article
C2 - 35386262
SN - 2296-2360
VL - 10
SP - 1
EP - 14
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 828448
ER -